Sirona Biochem Corp (SBM) - Total Liabilities

Latest as of July 2024: CA$4.27 Million CAD ≈ $3.09 Million USD

Based on the latest financial reports, Sirona Biochem Corp (SBM) has total liabilities worth CA$4.27 Million CAD (≈ $3.09 Million USD) as of July 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Sirona Biochem Corp to evaluate the company's liquid asset resilience ratio.

Sirona Biochem Corp - Total Liabilities Trend (2011–2023)

This chart illustrates how Sirona Biochem Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Sirona Biochem Corp (SBM) total assets.

Sirona Biochem Corp Competitors by Total Liabilities

The table below lists competitors of Sirona Biochem Corp ranked by their total liabilities.

Company Country Total Liabilities
Primeserv Group Ltd
JSE:PMV
South Africa ZAC80.45 Million
Mitra Angkasa Sejahtera PT Tbk
JK:BAUT
Indonesia Rp63.96 Billion
Dycasa SA
BA:DYCA
Argentina AR$23.74 Billion
RomReal Limited
OL:ROM
Norway Nkr675.00K
Northeast Electric Development Company Limited
F:NE4H
Germany €391.88 Million
InnSuites Hospitality Trust
NYSE MKT:IHT
USA $14.04 Million
Ekiz Kimya Sanayi ve Ticaret AS
IS:EKIZ
Turkey TL37.32 Million
Inepar S.A. Indústria e Construções
SA:INEP3
Brazil R$2.50 Billion

Liability Composition Analysis (2011–2023)

This chart breaks down Sirona Biochem Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See SBM equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.34 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.23 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 5.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sirona Biochem Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sirona Biochem Corp (2011–2023)

The table below shows the annual total liabilities of Sirona Biochem Corp from 2011 to 2023.

Year Total Liabilities Change
2023-10-31 CA$3.54 Million
≈ $2.56 Million
+229.26%
2022-10-31 CA$1.08 Million
≈ $778.50K
-22.27%
2021-10-31 CA$1.38 Million
≈ $1.00 Million
-33.75%
2020-10-31 CA$2.09 Million
≈ $1.51 Million
+1.09%
2019-10-31 CA$2.07 Million
≈ $1.50 Million
-31.80%
2018-10-31 CA$3.03 Million
≈ $2.19 Million
-7.90%
2017-10-31 CA$3.29 Million
≈ $2.38 Million
+110.75%
2016-10-31 CA$1.56 Million
≈ $1.13 Million
-21.95%
2015-10-31 CA$2.00 Million
≈ $1.45 Million
+22.20%
2014-10-31 CA$1.64 Million
≈ $1.18 Million
+36.84%
2013-10-31 CA$1.20 Million
≈ $865.73K
+22.51%
2012-10-31 CA$976.91K
≈ $706.69K
+33.42%
2011-10-31 CA$732.20K
≈ $529.66K
--

About Sirona Biochem Corp

V:SBM Canada Biotechnology
Market Cap
$11.23 Million
CA$15.53 Million CAD
Market Cap Rank
#26852 Global
#1103 in Canada
Share Price
CA$0.06
Change (1 day)
+0.00%
52-Week Range
CA$0.06 - CA$0.06
All Time High
CA$0.66
About

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. The company's programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, anti-wrinkle compound, and anti-viral program. The company … Read more